Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

MS1819-SD

Phase Two

Phase Two

Therapeutic Approach

Nutritional-GI

MS1819-SD is a non-porcine (not pig-derived) enzyme for individuals with CF who have exocrine pancreatic insufficiency. It is a man-made version of a lipase enzyme taken from the yeast Yarrowia lipolytica. This drug does not contain any animal products.

Status

In 2018, a phase 2a study of MS1819-SD was conducted in people with chronic pancreatitis. The study showed that MS1819-SD was safe and may potentially improve fat absorption.

A phase 2 study in people with CF is currently ongoing. This study will compare MS1819-SD to currently available porcine-derived enzymes.

Sponsor

This program is sponsored by AzurRx Biopharma. It is being conducted within the Therapeutics Development Network (TDN). 



Contact us about MS1819-SD >